Related Experiment Video
Updated: Nov 12, 2025

10:35
Measuring the Stiffness of Ex Vivo Mouse Aortas Using Atomic Force Microscopy
Published on: October 19, 2016
10.8K
Targeting Cell Stiffness: A Paradigm Shift in the Treatment of Aortic Stiffness
Marina Cecelja1, Catherine M Shanahan2
1Department of Clinical Pharmacology, St Thomas' Hospital, School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, United Kingdom (M.C.).
Circulation Research
|March 18, 2021
Abstract
No abstract available in PubMed .
Related Concept Videos
Atherosclerosis III: Management
110
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
110
Aortic Regurgitation III: Medical Management
155
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
155
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
657
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
657

